Atomoxetine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Jul 1, 2005 → Apr 1, 2008
NCT ID
NCT00953862About Atomoxetine
Atomoxetine is a pre-clinical stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00953862. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01177943 | Phase 1 | Completed |
| NCT00969618 | Phase 3 | Completed |
| NCT00760747 | Approved | Completed |
| NCT00687609 | Approved | Terminated |
| NCT00636818 | Phase 2 | Completed |
| NCT00530335 | Phase 2 | Completed |
| NCT00471354 | Approved | Completed |
| NCT00918567 | Approved | Completed |
| NCT00299234 | Approved | Terminated |
| NCT00320528 | Phase 3 | Completed |
| NCT00252278 | Approved | UNKNOWN |
| NCT00255138 | Phase 3 | Withdrawn |
| NCT00953862 | Pre-clinical | Completed |
| NCT00191633 | Approved | Completed |
| NCT00286949 | Pre-clinical | Completed |
| NCT00488163 | Approved | Completed |
| NCT00191737 | Phase 3 | Completed |
| NCT00191516 | Phase 3 | Completed |
| NCT00191880 | Phase 3 | Completed |
| NCT00191035 | Approved | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder